Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

NCT06872112 is registered in ClinicalTrials.gov with Joseph C. Wu as lead sponsor.

NCT NCT06872112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06872112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Lead sponsor
Joseph C. Wu
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2026
Completion date
January 1, 2029
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)